Source comparison
Preclinical Evidence vs Human Clinical Data
The strongest evidence for MOTS-c comes from rodent models. A 2020 study in Nature Medicine showed that aged mice (18 months old. Equivalent to ~60 years in humans) treated with MOTS-c for eight weeks experienced improved physical performance, reduced inflamma
This comparison does not assign a generated winner or score.
- The strongest evidence for MOTS-c comes from rodent models. A 2020 study in Nature Medicine showed that aged mice (18 months old. Equivalent to ~60 years in humans) treated with MOTS-c for eight weeks experienced improved physical performance, reduced inflammation markers, and 12% reduction in visceral adiposity compared to controls. The dose used was 15 mg/kg administered three times weekly via intraperitoneal injection. A route and frequency that doesn't translate directly to human subcutaneous protocols.
- Human data is significantly thinner. A 2021 pilot study published in Diabetes examined MOTS-c in 12 healthy male volunteers at a single 5mg dose. The primary endpoints were safety and glucose tolerance. Not fat loss. Results showed improved insulin sensitivity measured by hyperinsulinemic-euglycemic clamp, the gold standard for insulin sensitivity assessment, but the study duration was too short (single-dose pharmacokinetics tracked for 48 hours) to measure changes in body composition. No adverse events were reported, and plasma MOTS-c levels peaked at 90 minutes post-injection with a half-life of approximately 4.5 hours.
- The gap matters because preclinical dosing, administration routes, and metabolic baselines differ substantially from human application. Mice have metabolic rates 7–10 times higher than humans per kilogram of body weight, which means dose extrapolation isn't linear. The 15 mg/kg dose used in the Nature Medicine study would translate to over 1,000mg for a 70kg human. Far above the 5–15mg range used in early-phase human trials. There's no published Phase 3 trial examining MOTS-c for fat loss as a primary endpoint, and no FDA-approved indication exists for any condition.